Work

Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years

Year: 2025

Type: article

Abstract: Introduction: Bimekizumab (BKZ) has demonstrated long-term efficacy in patients (pts) with moderate to severe plaque psoriasis.1 Measuring response using absolute outcome scores may be clinically beneficial, as they are not influenced by baseline (BL) disease severity and provide a direct measure of current disease severity.2 We report improvements in absolute scores for psoriasis clinical outcomes through 4 years of BKZ treatment. Procedure: Data were pooled from BE VIVID/BE READY/BE SURE (NCT03370133/NCT03410992/NCT03412747) and their open-label extension (OLE) BE BRIGHT (NCT03598790). Included pts received BKZ 320 mg every 4 weeks (wks; Q4W) to Wk16, then Q4W or Q8W into OLE. Mean absolute Psoriasis Area and Severity Index (PASI), Investigator’s Global Assessment (IGA), body surface area (BSA) affected by psoriasis, and Dermatology Life Quality Index (DLQI) scores are reported to OLE Wk144 (Year4), using multiple imputation. Data were reported in all pts (BKZ Total), and in pts who received BKZ Q4W to Wk16 then Q8W (Q4W/Q8W). Results: Among 771 BKZ Total pts, mean BL scores were: PASI 21.1; IGA 3.3; BSA 27.0; DLQI 10.5 (Q4W/Q8W: PASI 20.4; IGA 3.3; BSA 24.5; DLQI 10.8). Mean Wk16/Year4 scores were: PASI 0.6/0.7; IGA 0.4/0.5; BSA 1.4/1.2; DLQI 1.3/0.9. Scores in the 197 Q4W/Q8W pts at Wk16/Year4 were similar (PASI 0.3/0.6; IGA: 0.3/0.3; BSA: 0.7/1.2; DLQI: 1.3/0.7). Conclusion: Improvements in mean absolute PASI, IGA, BSA, and DLQI were high by Wk16 and sustained through 4 years with BKZ.

Source: SKIN The Journal of Cutaneous Medicine

DOI: 10.25251/mextwf19